8-K: Avinger Secures Strategic Funding and Reports Q4 2023 Results, Eyes Coronary Market Entry

Avinger announced a strategic partnership with Zylox-Tonbridge, securing $15 million in funding, while reporting a 5% sequential revenue increase for Q4 2023 and advancing its coronary product development.

Summary

• Avinger reported its fourth quarter and full year 2023 financial results, highlighting a new strategic partnership with Zylox-Tonbridge.
• The partnership includes a $15 million financing agreement, with an initial $7.5 million equity investment completed in March 2024.
• Avinger's Q4 2023 revenue was $1.9 million, a 5% increase compared to the previous quarter, with a gross margin of 20%.
• The company expanded its sales team by over 25% and continued the commercial launch of Tigereye ST, its advanced CTO-crossing device.
• Avinger is also progressing with the development of its coronary CTO-crossing system, with an IDE submission anticipated in the third quarter of 2024.
• The company's net loss for Q4 2023 was $5.0 million, and adjusted EBITDA was a loss of $4.3 million.
• Cash and cash equivalents totaled $5.3 million as of December 31, 2023, with an additional $7.5 million raised in March 2024.
• Avinger's debt was restructured with principal payments extended to 2027 and a conversion of preferred stock.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic partnership and product development progress are positive, the financial results show a decline in gross margin and increased losses. The sentiment is neutral to slightly negative due to the financial performance.

Positives

• The strategic partnership with Zylox-Tonbridge provides significant funding and access to the Chinese market.
• Avinger achieved a 5% sequential increase in revenue in Q4 2023.
• The company expanded its sales team by more than 25%, indicating a focus on growth.
• The development of the coronary CTO-crossing system is progressing, with an IDE submission anticipated in Q3 2024.
• The debt restructuring provides financial flexibility by extending principal payments to 2027.
• The conversion of preferred stock eliminates liquidation and dividend preferences.

Negatives

• Avinger experienced a decrease in gross margin to 20% in Q4 2023, compared to 34% in Q4 2022.
• The company reported a net loss of $5.0 million for Q4 2023.
• Adjusted EBITDA was a loss of $4.3 million for Q4 2023.
• Operating expenses increased to $5.0 million in Q4 2023, primarily due to sales headcount and transaction costs.

Risks

• Avinger is dependent on a limited number of products.
• The company faces risks related to the development and regulatory approval of new products.
• The adoption of Avinger's products by physicians is uncertain.
• The company's financial performance is subject to market conditions and competition.
• The company's ability to achieve profitability is not guaranteed.

Future Outlook

Avinger anticipates the full commercial launch of its Pantheris LV system later in the year and plans to file an IDE application for its coronary CTO-crossing system in the third quarter of 2024. The company also expects to benefit from its partnership with Zylox-Tonbridge, including access to the Chinese market and potential cost efficiencies.

Management Comments

• Jeff Soinski, Avinger's President and CEO, stated that the partnership with Zylox-Tonbridge provides strategic equity funding and opens a commercial channel for Avinger products in China.
• Management believes that the company's image-guided approach has the potential to redefine the coronary CTO-crossing market.

Industry Context

This announcement highlights Avinger's efforts to expand its market reach and product portfolio, particularly in the coronary space, which is a large and underserved market. The partnership with Zylox-Tonbridge is a strategic move to leverage international markets and potentially reduce manufacturing costs. This is in line with the trend of medical device companies seeking strategic partnerships to drive growth and innovation.

Comparison to Industry Standards

• Avinger's Q4 2023 revenue of $1.9 million is relatively low compared to larger medical device companies, such as Medtronic or Boston Scientific, which report billions in quarterly revenue.
• The 20% gross margin is also lower than the industry average for medical device companies, which often exceeds 50%.
• The company's focus on image-guided technology for vascular disease treatment is a differentiating factor, but its financial performance needs improvement to compete effectively with established players.
• The strategic partnership with Zylox-Tonbridge is similar to other medical device companies that seek international partnerships to expand their market reach and reduce costs, such as Stryker's partnerships in Asia.

Stakeholder Impact

• Shareholders will be impacted by the strategic partnership and the company's financial performance.
• Employees may be affected by the sales team expansion and the company's growth initiatives.
• Customers will benefit from the launch of new products and the expansion of Avinger's market presence.
• Suppliers may see increased demand as Avinger expands its operations.
• Creditors will be impacted by the debt restructuring and the company's financial performance.

Next Steps

• Avinger will continue the full commercial launch of the Pantheris LV image-guided atherectomy system.
• The company plans to submit an IDE application for its coronary CTO-crossing system in the third quarter of 2024.
• Avinger will work with Zylox-Tonbridge to develop a more cost-efficient manufacturing structure.
• The company will explore opportunities to distribute Zylox-Tonbridge's products in the U.S. and Germany.

Key Dates

Keywords

Avinger, Zylox-Tonbridge, medical devices, vascular disease, coronary CTO, Tigereye ST, Pantheris LV, atherectomy, strategic partnership, financial results, IDE submission, sales growth